myasthenia gravis l.
Skip this Video
Loading SlideShow in 5 Seconds..
Myasthenia Gravis PowerPoint Presentation
Download Presentation
Myasthenia Gravis

Loading in 2 Seconds...

play fullscreen
1 / 10

Myasthenia Gravis - PowerPoint PPT Presentation

Download Presentation
Myasthenia Gravis
An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Myasthenia Gravis • Disease of the neuromuscular junction characterized by fluctuating weakness of certain skeletal muscle groups. Neurology Chapter of IAP

  2. Myasthenia Gravis(MG) • Acetycholine (ACh) is an important neurotransmitter that stimulates muscle tissue to contract. • MG is an autoimmune disease in which antibodies are formed against ACh and a reduction in ACh receptor sites at the neuromuscular junction. Neurology Chapter of IAP

  3. Neurology Chapter of IAP

  4. Pathophysiology • Loss of muscle strength. • There is no single cause identified, however, thymic tumors and viral infections have been found in a certain number of patients. Neurology Chapter of IAP

  5. Clinical manifestations • Primary s/s= easy fatigability of skeletal muscle during activity. • Muscles involved: eyes and eyelids, chewing, swallowing, speaking, and breathing. • Fluctuating weakness: usually strong in the a.m., progressively weaker with activity. Neurology Chapter of IAP

  6. Clinical Manifestations • 90% of patients have eye involvement • Facial mobility may be impaired • Muscles of limb and trunk less often affected. • No sensory or reflex loss; muscle atrophy is rare. Neurology Chapter of IAP

  7. Clinical manifestations • Variable course • May be precipitated by emotional stress, pregnancy, menses, secondary illness, trauma, temperature extremes, hypokalemia, ingestion of drugs with neuromuscular blocking agents, surgery. Neurology Chapter of IAP

  8. Complications • Aspiration, respiratory insufficiency, and respiratory infection • Acute exacerbation called myasthenic crisis. • The opposite of this is a cholinergic crisis and results from overdose of cholinergic drugs. Neurology Chapter of IAP

  9. Diagnostic studies • Assessment: • Have pt look up for 2-3 minutes; if MG, patient will have increased droop of eyelids. • EMG may show muscle fatigue • Tensilon test- in MG reveal improved muscle contractility after IV anticholinesterase agent edrophonium chloride (tensilon) • Also diagnosis cholinergic crisis- muscle weakness gets worse • Keep atropine on hand to counteract effects of tensilon Neurology Chapter of IAP

  10. Therapeutic management • Anticholinesterase inhibitors-prevents anticholinestersase from breaking down ACh; helps neurotransmission. Monitor dose! • Mestinon, Prostigmine Corticosteroids- decrease immune response Prednisone Plasmapheresis- removes ACh antibodies and short-term improvement. Neurology Chapter of IAP